TY - JOUR
T1 - Photodynamic therapy outcome for oral verrucous hyperplasia depends on the clinical appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion
AU - Yu, Chuan Hang
AU - Chen, Hsin Ming
AU - Hung, Hsien Yen
AU - Cheng, Shih Jung
AU - Tsai, Tsuimin
AU - Chiang, Chun Pin
N1 - Funding Information:
This study was supported by research grants of NSC90-2736-L-002-002 and NSC90-2736-L-002-003 from the National Science Council, Taipei, Taiwan as well as supported by research grants of NTUH94-S183, NTUH95-383, and NTUH96-563 from the National Taiwan University Hospital, Taipei, Taiwan. The authors thank Industrial Technology Research Institute of Taiwan for the development of the light-emitting diode source.
PY - 2008/6
Y1 - 2008/6
N2 - Our previous studies showed that oral verrucous hyperplasia (OVH) lesions can be successfully treated with a topical 5-aminolevulinic acid-mediated photodynamic therapy (topical ALA-PDT) protocol using a 635-nm light-emitting diode light source. In this study, we report the clinical outcomes of 36 OVH lesions treated by this protocol and assess what clinicopathological parameters of OVH lesions could influence PDT treatment outcomes. We found that all the 36 OVH lesions showed complete response (CR) after an average of 3.8 (range, 1-6) treatments of topical ALA-PDT. OVH lesions with an clinical appearance of a mass, with the greatest diameter <1.5 cm, with the pink color, with epithelial dysplasia, or with the surface keratin layer ≦40 μm needed significantly less mean treatment numbers of PDT to achieve a CR than OVH lesions with an outer appearance of a plaque or a combination type of peripheral plaque and central mass (p = 0.000), with the greatest diameter ≧1.5 cm (p = 0.011), with the white color (p = 0.000), without epithelial dysplasia (p = 0.043), or with the surface keratin layer >40 μm (p = 0.003), respectively. Multivariate analysis showed that only the clinical appearance of OVH lesions was the independent factor (p = 0.0069). We conclude that complete regression of OVH lesions can be achieved by less than seven treatments of topical ALA-PDT once a week. The PDT treatment outcome for OVH depends on the outer appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion.
AB - Our previous studies showed that oral verrucous hyperplasia (OVH) lesions can be successfully treated with a topical 5-aminolevulinic acid-mediated photodynamic therapy (topical ALA-PDT) protocol using a 635-nm light-emitting diode light source. In this study, we report the clinical outcomes of 36 OVH lesions treated by this protocol and assess what clinicopathological parameters of OVH lesions could influence PDT treatment outcomes. We found that all the 36 OVH lesions showed complete response (CR) after an average of 3.8 (range, 1-6) treatments of topical ALA-PDT. OVH lesions with an clinical appearance of a mass, with the greatest diameter <1.5 cm, with the pink color, with epithelial dysplasia, or with the surface keratin layer ≦40 μm needed significantly less mean treatment numbers of PDT to achieve a CR than OVH lesions with an outer appearance of a plaque or a combination type of peripheral plaque and central mass (p = 0.000), with the greatest diameter ≧1.5 cm (p = 0.011), with the white color (p = 0.000), without epithelial dysplasia (p = 0.043), or with the surface keratin layer >40 μm (p = 0.003), respectively. Multivariate analysis showed that only the clinical appearance of OVH lesions was the independent factor (p = 0.0069). We conclude that complete regression of OVH lesions can be achieved by less than seven treatments of topical ALA-PDT once a week. The PDT treatment outcome for OVH depends on the outer appearance, size, color, epithelial dysplasia, and surface keratin thickness of the lesion.
KW - 5-Aminolevulinic acid
KW - Oral verrucous hyperplasia
KW - Topical photodynamic therapy
UR - http://www.scopus.com/inward/record.url?scp=43449110454&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43449110454&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2007.08.016
DO - 10.1016/j.oraloncology.2007.08.016
M3 - Article
C2 - 18203648
AN - SCOPUS:43449110454
SN - 1368-8375
VL - 44
SP - 595
EP - 600
JO - Oral Oncology
JF - Oral Oncology
IS - 6
ER -